

Prostate cancer liquid biopsy test, 6/16

June 2016—MDxHealth announced the commercial launch of its SelectMDx for Prostate Cancer test in the U.S. as a laboratory developed test. Testing will be conducted at MDxHealth's CAP- and CLIA-accredited laboratory facilities in Irvine, Calif.

The SelectMDx test has been validated as a urine-based, noninvasive liquid biopsy method to identify men at risk for aggressive, potentially lethal prostate cancer who may benefit from an initial prostate biopsy or magnetic resonance imaging and early detection. With a negative predictive value of 98 percent for high-grade disease, SelectMDx also helps identify men at very low risk for clinically significant cancer, and could reduce unnecessary invasive biopsies by approximately 50 percent.

[**MDxHealth**](#), 949-812-6979